Pivotal clinical trials and a meta-analysis have shown that the combination of CDK 4/6 inhibitors with ET prolongs survival in patients with advanced HR+/HER2– breast cancer [21–24]. This evidence concerns the gene ERBB2 and breast carcinoma.